Kura Oncology (KURA) EBITDA (2010 - 2026)
Kura Oncology (KURA) reported EBITDA of -$74.7 million for Q1 2026, down 30.62% year-over-year from -$107.7 million in Q1 2025, and up 7.61% on a QoQ basis from -$80.9 million in Q4 2025.
Kura Oncology (KURA) has 17 years of EBITDA data on file, last reported at -$74.7 million in Q1 2026.
- Quarterly EBITDA fell 30.62% year-over-year to -$74.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$295.9 million (down 64.31% YoY) and the FY2025 annual result came in at -$278.4 million, down 61.91% from the prior year.
- EBITDA climbed to -$74.7 million in Q1 2026 per KURA's latest filing, from -$80.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$19.6 million in Q4 2024 and bottomed at -$80.9 million in Q4 2025.
- The 5-year median for EBITDA is -$40.5 million (2023), against an average of -$47.8 million.
- The widest annual swing landed in 2024, when EBITDA jumped 51.71%; it then plunged 313.37% in 2025.
- Tracing KURA's EBITDA over 5 years: stood at -$31.7 million in 2022, then dropped by 27.71% to -$40.5 million in 2023, then jumped by 51.71% to -$19.6 million in 2024, then sank by 313.37% to -$80.9 million in 2025, then rose by 7.61% to -$74.7 million in 2026.
- Per Business Quant, the three latest KURA EBITDA figures stand at -$74.7 million (Q1 2026), -$80.9 million (Q4 2025), and -$73.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Kura Oncology | 801.92 Mn | 801.92 Mn | 18.00 Mn | -74.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.74 Mn |
| Dec 31, 2025 | -80.89 Mn |
| Sep 30, 2025 | -73.91 Mn |
| Jun 30, 2025 | -66.39 Mn |
| Mar 31, 2025 | -57.22 Mn |
| Dec 31, 2024 | -19.57 Mn |
| Sep 30, 2024 | -52.83 Mn |
| Jun 30, 2024 | -50.48 Mn |
| Mar 31, 2024 | -49.07 Mn |
| Dec 31, 2023 | -40.52 Mn |
| Sep 30, 2023 | -36.92 Mn |
| Jun 30, 2023 | -36.50 Mn |
| Mar 31, 2023 | -31.93 Mn |
| Dec 31, 2022 | -31.73 Mn |
| Sep 30, 2022 | -37.11 Mn |
| Jun 30, 2022 | -35.94 Mn |
| Mar 31, 2022 | -37.31 Mn |
| Dec 31, 2021 | -34.34 Mn |
| Sep 30, 2021 | -33.17 Mn |
| Jun 30, 2021 | -33.97 Mn |
| Mar 31, 2021 | -30.82 Mn |
| Dec 31, 2020 | -26.34 Mn |
| Sep 30, 2020 | -24.10 Mn |
| Jun 30, 2020 | -20.49 Mn |
| Mar 31, 2020 | -18.98 Mn |
| Dec 31, 2019 | -17.87 Mn |
| Sep 30, 2019 | -16.22 Mn |
| Jun 30, 2019 | -14.80 Mn |
| Mar 31, 2019 | -13.79 Mn |
| Dec 31, 2018 | -16.11 Mn |
| Sep 30, 2018 | -15.04 Mn |
| Jun 30, 2018 | -14.76 Mn |
| Mar 31, 2018 | -14.62 Mn |
| Dec 31, 2017 | -10.78 Mn |
| Sep 30, 2017 | -9.33 Mn |
| Jun 30, 2017 | -7.82 Mn |
| Mar 31, 2017 | -7.53 Mn |
| Dec 31, 2016 | -7.38 Mn |
| Sep 30, 2016 | -6.96 Mn |
| Jun 30, 2016 | -6.63 Mn |
| Mar 31, 2016 | -6.53 Mn |
| Dec 31, 2015 | -6.56 Mn |
| Sep 30, 2015 | -6.08 Mn |
| Jun 30, 2015 | -5.60 Mn |
| Mar 31, 2015 | -4.48 Mn |
| Dec 31, 2014 | -3.67 Mn |
| Sep 30, 2014 | -66,000.00 |
| Jun 30, 2014 | -5,242.00 |
| Mar 31, 2014 | -4,138.00 |
| Dec 31, 2013 | -8,087.00 |
| Sep 30, 2013 | -4,475.00 |
| Jun 30, 2013 | -5,456.00 |
| Mar 31, 2013 | -4,716.00 |
| Dec 31, 2012 | -8,376.00 |
| Sep 30, 2012 | -4,728.00 |
| Jun 30, 2012 | -4,996.00 |
| Mar 31, 2012 | -4,241.00 |
| Dec 31, 2011 | -7,976.00 |
| Sep 30, 2011 | -5,360.00 |
| Jun 30, 2011 | -5,837.00 |
| Mar 31, 2011 | -4,266.00 |
| Dec 31, 2010 | -7,214.00 |
| Sep 30, 2010 | -4,238.00 |